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Despite the high prevalence and poor outcome of patients with metastatic lung 
cancer, the mechanisms of tumour progression and metastasis remain largely 
uncharacterized. We modelled human lung adenocarcinoma, which frequently 
harbours activating point mutations in KRAS1 and inactivation of the p53-
pathway2, using conditional alleles in mice3-5. Lentiviral-mediated somatic 
activation of oncogenic Kras and deletion of p53 in the lung epithelial cells of 
KrasLSL-G12D/+;p53flox/flox  mice initiates lung adenocarcinoma development4.  
Although tumours are initiated synchronously by defined genetic alterations, only 
a subset become malignant, suggesting that disease progression requires additional 
alterations. Identification of the lentiviral integration sites allowed us to distinguish 
metastatic from non-metastatic tumours and determine the gene expression 
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alterations that distinguish these tumour types. Cross-species analysis identified 
the NK-2 related homeobox transcription factor Nkx2-1 (Ttf-1/Titf1) as a 
candidate suppressor of malignant progression. In this mouse model, 
downregulation of Nkx2-1 is pathognomonic of high-grade poorly differentiated 
tumours. Gain- and loss-of-function experiments in cells derived from metastatic 
and non-metastatic tumours demonstrated that Nkx2-1 controls tumour 
differentiation and limits metastatic potential in vivo. Interrogation of Nkx2-1 
regulated genes, analysis of tumours at defined developmental stages, and 
functional complementation experiments indicate that Nkx2-1 constrains tumours 
in part by repressing the embryonically-restricted chromatin regulator Hmga2. 
While focal amplification of NKX2-1 in a fraction of human lung adenocarcinomas 
has focused attention on its oncogenic function6-9, our data specifically link Nkx2-1 
downregulation to loss of differentiation, enhanced tumour seeding ability, and 
increased metastatic proclivity. Thus, the oncogenic and suppressive functions of 
Nkx2-1 in the same tumour type substantiate its role as a dual function lineage 
factor. 
We developed lentiviral vectors that express Cre-recombinase (Lenti-Cre)10 and 
determined the dose that results in 5 to 20 lung tumours per KrasLSL-G12D/+;p53flox/flox 
mouse after intratracheal administration. Mice with this tumour multiplicity lived 8-14 
months after tumour initiation and developed frequent macroscopic metastases to the 
draining lymph nodes, pleura, kidneys, heart, adrenal glands, and liver (Supplementary 
Fig. 1). Because lentiviruses integrate stably into the genome, the integration site was a 
unique molecular identifier that unambiguously linked primary tumours to their related 
metastases (Fig. 1a). We used linker-mediated PCR (LM-PCR) to determine the 
genomic sequence directly 3’ of the integrated lentiviral genome followed by a specific 
PCR for the lentiviral integration site (Fig. 1b). To have samples of sufficient quantity 
and purity for our analyses, we derived cell lines from primary tumours and metastases. 
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Cell lines were composed of pure tumour cells as determined by complete 
recombination of the p53floxed alleles (data not shown). The clonal relationship of these 
cell lines was established using LM-PCR or Southern blot analysis for the lentiviral 
genome (Fig. 1c and data not shown). We termed cell lines derived from verified 
metastatic primary lung tumours TMet.  
Gene expression profiling was performed on cell lines from twenty-three lung tumours 
and metastases (nine metastases, seven TMet primary tumours, and seven potentially 
non-metastatic primary tumours). Using an unsupervised consensus clustering 
method11, we identified four cell lines from likely non-metastatic tumour samples that 
had highly concordant gene expression and were separate from all TMet and metastasis 
(Met) samples (Supplementary Fig. 2).  Therefore, we surmised that these could 
represent non-metastatic primary tumours and classified them TnonMet.  
To determine whether relevant phenotypic differences existed between TnonMet and TMet 
cell lines, we assayed their ability to establish experimental metastases. TMet cell lines 
consistently formed more tumour nodules in the liver after intrasplenic injection despite 
having equivalent proliferation rates in cell culture (Fig. 1d-e and Supplementary Fig. 
2). The differences between TnonMet and TMet in metastatic potential, gene expression 
profiles, and our subsequent analyses suggest that TnonMet cell lines likely originated 
from non-metastatic tumours.  
Significant gene expression alterations distinguished TnonMet from TMet and Met-derived 
cell lines (Fig. 1f and Supplementary Table 1), many of which were validated by qRT-
PCR, flow cytometry, and western blotting (data not shown). A gene expression 
signature generated by comparing TnonMet to TMet/Met samples predicted patient outcome 
in two human lung adenocarcinoma gene expression datasets12,13, suggesting the 
possibility of evolutionarily-conserved molecular mechanisms of tumour progression 
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(Supplementary Fig. 2). Thus, we integrated mouse and human data by comparing the 
differences in expression between TnonMet and TMet/Met samples with the association of 
human gene expression and patient survival (Fig. 2a). Two genes were particularly 
notable from this analysis: the NK-related homeobox transcription factor Nkx2-1 and 
the Nkx2-1 target gene surfactant protein B (Sftpb; Fig. 2a). Nkx2-1 regulates lung 
development and is expressed in Type II pneumocytes and bronchiolar cells in the 
adult14-16. Expression of Nkx2-1 was >10-fold higher in TnonMet samples, and higher 
NKX2-1 expression in human tumours correlated with longer survival. Of note, NKX2-1 
is focally amplified in ~10% of human lung adenocarcinomas, with previous functional 
data supporting oncogenic activity6-9. Conversely some, but not all, 
immunohistochemical analyses of NKX2-1 in lung adenocarcinoma suggest an 
association between NKX2-1-negative tumours and poor patient outcome17-19. Given the 
uncertain functional role of Nkx2-1 in human lung cancer, we focused on validating and 
characterizing the function of this transcription factor in suppressing tumour progression 
and metastasis. 
We confirmed reduced Nkx2-1 mRNA and protein in TMet and Met cell lines without 
evidence of focal genomic loss of this region (Fig. 2b, Supplemental Fig. 4, and data not 
shown). Analysis of tumours from our mouse model indicated that Nkx2-1 expression 
was consistently downregulated in high-grade poorly differentiated tumours (Fig. 2c-e 
and Supplementary Fig. 3). Nkx2-1 expression was also reduced in advanced KrasG12D-
driven lung adenocarcinomas with p53R270H or p53R172H point mutations4,20. Using our 
LM-PCR assay, we identified three primary lung tumours as metastatic based on the 
presence of metastases with the same lentiviral integration site (Fig. 1b and data not 
shown). These tumours each contained poorly differentiated areas that were Nkx2-1neg 
(Supplementary Fig. 6). Interestingly, Nkx2-1 expression was low/absent in almost all 
lymph node and distant macrometastases, though some micrometastases were Nkx2-1pos 
or Nkx2-1mixed (Supplementary Fig. 3). Whether certain micrometastases were seeded 
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by Nkx2-1pos cells or reverted to an Nkx2-1pos phenotype due to cues from their new 
environment is unknown.  
In human lung adenocarcinoma12,13 the expression of NKX2-1 correlated with a TnonMet 
gene expression signature derived from the mouse (TnonMet Signature; Fig. 2f and 
Supplementary Fig. 3). Additionally, the TnonMet signature was anti-correlated with an 
embryonic stem cell signature, supporting the notion that TMet/Met cells have 
transitioned to a less differentiated and more stem-like state21 (Fig. 2f and 
Supplementary Fig. 3).  
The correlative mouse and human data were consistent with Nkx2-1 being either a 
marker or a functional regulator of tumour progression. To interrogate the function of 
Nkx2-1, we reexpressed Nkx2-1 in a TMet cell line. Nkx2-1 reexpression greatly 
suppressed tumour formation after intravenous transplantation (Fig. 3a, 3b, 
Supplementary Fig. 5, and data not shown). Moreover, of the tumours that formed after 
injection of TMet-Nkx2-1 cells, many were either Nkx2-1neg or Nkx2-1mixed (Fig. 3c). In 
general, tumours that continued to express Nkx2-1 were well differentiated, while 
Nkx2-1neg tumours often displayed solid architecture or areas of poorly-differentiated 
cells (Fig. 3d and Supplementary Fig. 5).  Intrasplenic transplantation unveiled a similar 
diminution of tumour formation by TMet–Nkx2-1 cells (Supplementary Fig. 5). Nkx2-1 
reexpression did not alter proliferation or cell death in cell culture or affect tumour 
proliferation in vivo suggesting that Nkx2-1 specifically alters tumour seeding capacity 
(Supplementary Fig.5 and data not shown). Consistent with this hypothesis, Nkx2-1 
reexpression dramatically reduced the ability of these cells to grow in anchorage-
independent conditions and TMet–Nkx2-1 cells initiated tumours less efficiently after 
subcutaneous transplantation (Fig. 3e and Supplementary Fig. 5) 
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To further elucidate the functional effect of Nkx2-1 expression, we used RNAi to knock 
down Nkx2-1 in TnonMet cell lines. Expression of shNkx2-1 in TnonMet cells reduced 
Nkx2-1 mRNA and protein to levels similar to those in TMet cell lines (Supplementary 
Fig. 7 and data not shown). Nkx2-1 knockdown allowed the formation of more liver 
nodules after intrasplenic injection and more lung nodules after intravenous 
transplantation (Fig. 3f ). Furthermore, TnonMet-shNkx2-1 cells metastasized from these 
lung nodules to the draining mediastinal lymph nodes (data not shown). 
Mechanistically, Nkx2-1 knockdown did not alter proliferation or cell death in cell 
culture (Supplementary Fig. 7). However, Nkx2-1 knockdown enhanced the ability of 
cells to form colonies under anchorage-independence conditions and tumours after 
subcutaneous transplantation (Fig 3g and Supplementary Fig. 7) both of which are 
associated with increased cellular stress. To confirm that the effects of the shNkx2-1 
were specifically due to Nkx2-1 knockdown, we reexpressed an Nkx2-1 cDNA (Nkx2-
1*) containing four silent point mutations rendering it insensitive to our shNkx2-1. 
Expression of Nkx2-1* reverted the phenotypic alterations elicited by shNkx2-1 (Fig. 
3h). As a final test of the ability of Nkx2-1 to constrain tumour progression, we induced 
tumours in KrasLSL-G12D/+;p53flox/flox  mice with either Lenti-Cre or a lentiviral vector 
expressing both Nkx2-1 and Cre (Lenti-Nkx2-1/Cre). Expression of exogenous Nkx2-1 
limited tumour progression resulting in fewer tumours of advanced histopathological 
grades (Fig. 3i).  
To discover Nkx2-1 regulated genes, we compared gene expression in TnonMet and 
TnonMet–shNkx2-1 cells. Overlapping this gene list with the list of genes that are 
expressed at different levels in TnonMet versus TMet/Met cells uncovered a number of high 
priority candidate genes (Supplementary Fig. 8). We elected to focus on Hmga2 given 
its role in altering global gene expression through the regulation of chromatin structure 
and its association with embryonic and adult stem cell states22-25. Several reports 
suggest that Hmga2 can also be expressed in malignant tumours of diverse origins26-29. 
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Hmga2 is derepressed by Nkx2-1 knockdown in TnonMet cells and regions of 
KrasG12D/+;p53Δ/Δ tumours that lacked Nkx2-1 expression were almost universally 
Hmga2pos (Fig. 4a-c). Importantly, Nkx2-1neg areas of known metastatic primary 
tumours and of metastases were Hmga2pos (Supplementary Fig. 9 and data not shown). 
Additionally, Hmga2 was downregulated in TMet cells after reexpression of Nkx2-1 
cDNA and in TnonMet-shNkx2-1 cells after expression of Nkx2-1* (data not shown). 
Although Hmga2 can be regulated by the Let7 family of miRNAs22,26,30, Let7 levels, 
Lin28 expression, and Let7 activity were equivalent in TnonMet, TMet, and Met cell lines 
and were unaltered in TnonMet-shNkx2-1 cells (Supplementary Fig. 10 and data not 
shown). Hmga2 promoter activity was derepressed in TnonMet-shNkx2-1 cells and 
repressed in TMet-Nkx2-1 cells, indicating that expression of Hmga2 in lung 
adenocarcinoma cells is regulated through differential promoter activity (Supplementary 
Fig. 10).   
We hypothesized that lung adenocarcinomas progress from an Nkx2-1posHmga-2neg to 
an Nkx2-1negHmga-2pos state. However, metastatic and non-metastatic tumours could be 
fundamentally distinct at the time of initiation. Hmga2 is highly expressed in embryonic 
lung but not in any normal adult lung cells, and early after initiation, KrasG12D/+;p53Δ/Δ 
tumours were uniformly Nkx2-1posHmga-2neg (Fig. 4d, Supplementary Fig. 11 and data 
not shown). KrasG12D/+;p53-proficient tumours, which maintain their differentiated 
phenotype and never metastasize even late after tumour initiation5, were almost 
universally Nkx2-1posHmga-2neg (Fig. 4e and Supplementary Fig. 11). Finally, at later 
time points poorly differentiated areas of KrasG12D/+;p53Δ/Δ tumours with reduced 
Nkx2-1 expression were almost always associated with lower grade Nkx2-1-expressing 
areas (Supplementary Fig. 6). Collectively, these data indicate that lung 
adenocarcinomas undergo a transition towards a more aggressive Nkx2-1negHmga-2pos 
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phenotype and that a Nkx2-1-dependent gene expression program is a key regulator of 
this transition. 
We next analyzed the expression of NKX2-1 and HMGA2 in human adenocarcinomas. 
Although the expression patterns were diverse, two important conclusions could be 
made. First, tumours of the NKX2-1posHMGA2neg and NKX2-1negHMGA2pos 
phenotypes exist within the spectrum of human lung adenocarcinomas (Fig. 4f and 
Supplementary Fig. 10). Second, there was a trend towards well-differentiated tumours 
being NKX2-1pos/HMGA2neg whereas moderately and poorly differentiated tumours 
were more often represented by other combinations of these proteins. Most notably, the 
moderately and poorly differentiated groups contained NKX2-1neg/HMGA-2pos tumours 
(Fig. 4f). These results underscore the diversity within this single human tumour type 
and suggest that our genetically defined model likely represents, at the molecular level, 
a subset of these tumours.  
We next used RNAi to knockdown Hmga2 in TnonMet-shNkx2-1 cells to determine if this 
gene was required for their enhanced metastasis seeding potential. Hmga2 knockdown 
greatly reduced tumour formation after transplantation (Fig. 4g and Supplementary Fig. 
12). Finally, Hmga2 knockdown in a metastasis-derived cell line reduced anchorage-
independent growth and tumour seeding ability after transplantation (Fig 4h-i and 
Supplementary Fig. 12). Expression of HMGA2 correlates with poor outcome and the 
presence of metastases in several cancer types (Supplemental Fig. 9)26-29. A future 
challenge will be to understand the molecular mechanism by which Hmga2 controls 
lung adenocarcinoma metastatic potential. The expansion of Nkx2-1negHmga-2pos 
regions within primary lung tumours suggests the acquisition of phenotypes that are 
advantageous to the primary tumours and also increase the probability of metastatic 
spread.  
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The fact that NKX2-1 can have both oncogenic and tumour suppressive functions in 
lung cancer presumably represents dichotomous functions within the distinct context of 
individual tumours of the same type. Lung adenocarcinomas may be diverse in their cell 
of origin, mutation spectrum, or gene expression leading to a differential requirement 
for continued NKX2-1 expression and different ability to tolerate or benefit from 
NKX2-1 downregulation. Our results emphasize the power of genetically-engineered 
mouse models of advanced disease, used in conjunction with human studies, to 
elucidate mechanisms that control cancer progression and metastatic spread. Through 
this approach we identify one molecular mechanism by which a highly prevalent tumour 
type can progresses to its malignant state.  
 
Methods Summary 
Mice, tumour initiation, and derivation of cell lines. KrasLSL-G12D, p53flox, p53LSL-
R270H, and p53LSL-R172H mice have been described3,5,20. Tumours were initiated by 
intratracheal infection of mice with a lentiviral vector expressing Cre-recombinase10. 
The MIT Institutional Animal Care and Use Committee approved all animal studies and 
procedures. Cell lines were created by enzymatic and mechanical dissociation of 
individual lung tumours and metastases harvested from mice 8-14 months after tumour 
initiation.  
LM-PCR, Southern blotting, and gene expression analysis. LM-PCR was performed 
with forward primers specific for the lentiviral LTR. Southern blotting used Cre probe 
and standard methods. RNA was extracted using Trizol, analyzed for RNA integrity and 
prepared with Affymetrix GeneChip® WT Sense Target Labelling and Control Reagents 
kit, followed by hybridization to Affymetrix GeneChip® Mouse Exon 1.0 ST Arrays.  
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Protein and RNA analysis. Western blotting used standard methods and antibodies to 
Nkx2-1 (Epitomics, Inc), Hmga2 (BioCheck, Inc), and Hsp90 (BD Transduction 
Laboratories) as a loading control. Immunohistochemistry was performed on formalin-
fixed, paraffin-embedded 4µm sections using the ABC Vectastain kit (Vector 
Laboratories) with antibodies described above. Sections were developed with DAB and 
counterstained with hematoxylin.  
Gene expression and knockdown. Nkx2-1 was stably knocked-down with a pLKO-
based lentiviral vector (OpenBiosystems/TRC). MSCV-Puro retroviral vectors were 
used for stable expression of Nkx2-1 and Nkx2-1* (created with 4 silent mutations 
using QuikChange® Lightning Site-Directed Mutagenesis (Stratagene). Hmga2 was 
stably knocked-down with an MSCV-Hygro retroviral vector.  
Transplantation experiments. For intravenous transplantation 105 cells resuspended in 
200µl PBS were injected in the lateral tail vein. For intrasplenic transplantation 105 cells 
resuspended in 50µl PBS. In all graphs each circle represents an individual mouse and 
the bar represents the mean. Statistical significance was determined using the Student’s 
t-test. 
Supplementary Information is linked to the online version of the paper at www.nature.com/nature. 
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Figure 1. A lentiviral-vector induced mouse model of lung 
adenocarcinoma identifies gene expression alterations during tumour 
progression. a, Infection of KrasLSL-G12D/+;p53flox/flox mice with Cre-expressing 
lentiviral vectors initiates lung adenocarcinoma. b, Linker-mediated PCR cloning 
of the lentiviral integration site in metastases (Met) allows specific PCR 
amplification of that lentiviral-integration (lower band) to identify which primary 
tumour gave rise to the metastases. Top band is a control product. c, Southern 
blot for the integrated lentiviral genome on cell lines. d, Representative images 
of livers after intrasplenic transplantation of TnonMet or TMet  cells. Scale bar = 
0.5cm. e, Quantification of liver nodules after intrasplenic injection of two TnonMet 
and TMet cell lines. f, Gene expression alterations (log2) between TnonMet and 
TMet/Met samples.  
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Figure 2. Reduced Nkx2-1 in advanced lung adenocarcinoma correlates 
with a less differentiated state. a, Cross-species analysis of human lung 
adenocarcinoma patient outcome (likelihood ratio with the sign from correlation 
value) versus differential gene expression in murine TnonMet cells. b, Nkx2-1 
protein is absent from TMet and Met-derived cell lines. c-d, Nkx2-1 expression is 
high in well differentiated adenomas and early murine adenocarcinoma (top) but 
is downregulated in moderately to poorly differentiated advanced carcinomas 
(bottom).  Scale bar = 50µm. Upper inlay Nkx2-1 staining. Lower inlay H+E 
staining. e, Quantification of Nkx2-1 expression in murine lung tumours relative 
to tumour grade from most differentiated (atypical adenomous hyperplasia 
(AAH)) to least differentiated (Poor)). f, Relative NKX2-1 expression (log2) in 
human lung adenocarcinomas correlates with a TnonMet signature (r2 = 0.36). 
The TnonMet signature and an ES cell signature anti-correlate (r2 = -0.44). Each 
vertical bar represents a lung adenocarcinoma sample. Scale bar indicates the 
signature score. 
 
Figure 3. Nkx2-1 controls lung adenocarcinoma differentiation and 
restricts metastatic ability. a,  Nkx2-1 protein reexpression in TMet cells. b, 
Nkx2-1 reexpression reduces lung nodule formation after intravenous 
transplantation. p < 0.002. c, Quantification of Nkx2-1 in lung nodules after TMet 
or TMet-Nkx2-1 transplantation. n=3/group. d,  Association of Nkx2-1 expression 
with differentiation state in tumours after TMet or TMet-Nkx2-1 transplantation. 
Fisher’s exact test on the association of differentiation state with Nkx2-1 p < 
0.002. e, Nkx2-1 reexpression reduces anchorage-independent growth of TMet 
cells. Representative images and colony number (mean +/- SD of quadruplicate 
13 
wells, p < 0.0001). f, Nkx2-1 knockdown increases liver nodules after 
intrasplenic and lung nodules after intravenous transplantation of TnonMet cells. 
Representative of 7 mice/group. g, shNkx2-1 enhanced anchorage-independent 
growth of TnonMet cells. Representative images and colony number (mean +/- SD 
of triplicate wells, p < 0.0001). h, Restoration of Nkx2-1 expression with an 
shRNA-insensitive Nkx2-1 (Nkx2-1*) in TnonMet-shNkx2-1 cells reverts the 
enhanced lung nodule formation after intravenous transplantation. Mean +/- SD, 
n=3/group. i. Induction of tumours in KrasLSL-G12D/+;p53flox/flox mice with Nkx2-
1/Cre lentivirus reduces the development of advanced tumours (grades 3&4). 
Numbers indicate percent of tumours in each group.  
 
Figure 4. Nkx2-1 regulates the expression of Hmga2 in advanced lung 
adenocarcinoma. a, Nkx2-1 knockdown allows Hmga2 upregulation in TnonMet 
cells. b-c, Hmga2 and Nkx2-1 are reciprocally expressed in KrasG12D/+;p53Δ/Δ 
murine lung adenocarcinomas. Scale bar = 50µm. Inlaid images show cellular 
features and protein localization. Fisher’s exact test, p-value < 10-11. d, Early 
KrasG12D/+;p53Δ/Δ tumours are Nkx2-1posHmga2neg. e, KrasG12D-only tumours are 
Nkx2-1posHmga2neg. f, Expression of NKX2-1 and HMGA2 in human lung 
adenocarcinomas distributed by differentiation state. Large numbers are 
percentages. Small numbers are absolute number. g, Hmga2 knockdown 
reduces the tumourigenic potential of TnonMet-shNkx2-1 cells after intravenous 
transplantation. Control samples include the parental TnonMet-shNkx2-1 cells 
(grey circle) and cells infected by a control retrovirus (black circles). p < 0.003. 
h, shHmga2 reduces anchorage-independent growth of a metastasis-derived 
cell line (Met). Representative images and colony number (mean +/- SD of 
14 
quadruplicate wells, p < 0.0001). i, shHmga2 reduces the tumour-seeding 
potential of a Met cell line after intravenous transplantation. p <0.0001. 
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